HD-tDCS effects on social impairment in autism spectrum disorder with sensory processing abnormalities: a randomized controlled trial.

Publication date: Mar 21, 2025

This study examined the effects of high-definition transcranial direct current stimulation (HD-tDCS) on social impairment in children with autism spectrum disorder (ASD), focusing on those with and without sensory processing abnormalities. A randomized double-blind sham-controlled trial involved 72 children with ASD, divided into three groups based on sensory integration status. A post-hoc analysis of 51 children aged 4-8 years who received true HD-tDCS was conducted, categorizing them into hypo-tactile, hyper-tactile, and typical tactile sensitivity groups. Therapeutic efficacy was compared across these groups. (1) The randomized cntrolled Trial: The typical sensory integration group showed significant improvements in social awareness (t = 5. 032, p 

Open Access PDF

Concepts Keywords
Autism Autism Spectrum Disorder
Blind Autism spectrum disorder
Hd Child
Integration Child, Preschool
Transcranial Double-Blind Method
Female
Humans
Male
Sensory abnormalities
Sensory integration dysfunction
Social Behavior
Social impairment
Treatment Outcome

Semantics

Type Source Name
disease MESH autism spectrum disorder
disease MESH abnormalities
drug DRUGBANK Ranitidine
disease MESH neurodevelopmental disorder
pathway REACTOME Sensory Perception
disease MESH etiology
drug DRUGBANK Coenzyme M
drug DRUGBANK Isoxaflutole
disease MESH depressive disorder
disease MESH attention deficit hyperactivity disorder
disease MESH Parkinson’s disease
disease MESH stroke
disease MESH epilepsy
disease MESH numbness
disease MESH SID
disease MESH psychiatric disorders
disease MESH hypersensitivity
disease MESH dual diagnosis
disease MESH Autism
disease MESH handedness
drug DRUGBANK Aspartame
drug DRUGBANK Trestolone
drug DRUGBANK Etoperidone
disease MESH erythema
disease MESH night terrors
disease MESH seizures
disease MESH visual impairments
drug DRUGBANK Methionine
disease MESH facial expressions
pathway REACTOME Methylation
drug DRUGBANK gamma-Aminobutyric acid
drug DRUGBANK Ketamine
drug DRUGBANK Dopamine
disease MESH privacy
drug DRUGBANK Esomeprazole
disease MESH Developmental Disabilities
drug DRUGBANK Guanosine
disease MESH cerebellar ataxia
disease MESH dysphagia
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH anxiety
disease MESH developmental coordination disorder
pathway REACTOME Pervasive developmental disorders
disease MESH dyslexia
disease MESH Learning Disorders
drug DRUGBANK D-Alanine
drug DRUGBANK Baclofen
drug DRUGBANK Oxytocin
pathway REACTOME Reproduction

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *